Linked Life Data

50917

Source:http://linkedlifedata.com/resource/pubmed/id/50917

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
36
pubmed:dateCreated
1975-12-4
pubmed:abstractText
The therapeutic effectiveness of aprindine (Amidonal) was evaluated by trend analyses in 25 patients with predominantly severe forms of ventricular extrasystoles. The arrhythmia was stopped or improved in most instances. Severe side-effects for which the drug had to be discontinued occurred in three patients. The drug has a long half-life (about 20-30 hours). As a result, there can be cumulative dose-dependent side-effects, largely of a CNS type, disappearing after the dose has been reduced. Thirteen patients continued to be treated on an ambulatory basis, the oral maintenance dose averaging 100 mg/d, the mean follow-up period 11 1/2 months. There was no evidence of side-effects on liver, electrolytes, renal function or blood.
pubmed:language
ger
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Sep
pubmed:issn
0012-0472
pubmed:author
pubmed:issnType
Print
pubmed:day
5
pubmed:volume
100
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1764-7
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed:year
1975
pubmed:articleTitle
[Clinical observations of the new anti-arrhythmic drug aprindine from long-term trend analyses(author's transl)].
pubmed:publicationType
Journal Article, English Abstract